** Shares of drug developer Q32 Bio QTTB.O fall 65.3% to $8.46 premarket
** QTTB, late on Tuesday, said its experimental drug bempikibart failed to meet the main goal in a part of a mid-stage trial studying it in patients with atopic dermatitis
** The two-part trial was evaluating the drug in adults with atopic dermatitis, a condition that causes dry, itchy and inflamed skin
** Co plans to conduct a review to better understand the results
** Up to last close, stock has more than doubled YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.